The value of demonstration projects for new interventions: The case of human papillomavirus vaccine introduction in low- and middle-income countries

被引:17
作者
Howard, N. [1 ]
Mounier-Jack, S. [1 ]
Gallagher, K. E. [2 ,3 ]
Kabakama, S. [3 ]
Griffiths, U. K. [1 ]
Feletto, M. [4 ]
LaMontagne, D. S. [4 ]
Burchett, H. E. D. [1 ]
Watson-Jones, D. [2 ,3 ]
机构
[1] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, Tavistock Pl, London, England
[2] London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London, England
[3] Natl Inst Med Res, Mwanza Intervent Trials Unit, Mwanza, Tanzania
[4] PATH, Vaccine Access & Delivery, Seattle, WA USA
基金
比尔及梅琳达.盖茨基金会;
关键词
demonstration projects; HPV; low and middle-income countries; Papillomavirus; vaccination; DELIVERY STRATEGIES; HIGH COVERAGE;
D O I
10.1080/21645515.2016.1178433
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Demonstration projects or pilots of new public health interventions aim to build learning and capacity to inform country-wide implementation. Authors examined the value of HPV vaccination demonstration projects and initial national programmes in low-income and lower-middle-income countries, including potential drawbacks and how value for national scale-up might be increased. Data from a systematic review and key informant interviews, analyzed thematically, included 55 demonstration projects and 8 national programmes implemented between 2007-2015 (89years' experience). Initial demonstration projects quickly provided consistent lessons. Value would increase if projects were designed to inform sustainable national scale-up. Well-designed projects can test multiple delivery strategies, implementation for challenging areas and populations, and integration with national systems. Introduction of vaccines or other health interventions, particularly those involving new target groups or delivery strategies, needs flexible funding approaches to address specific questions of scalability and sustainability, including learning lessons through phased national expansion.
引用
收藏
页码:2475 / 2477
页数:3
相关论文
共 16 条
  • [1] [Anonymous], 2013, HPV VACC COMM SPEC C
  • [2] [Anonymous], CERV CANC ACT PROGR
  • [3] [Anonymous], ED ENR LEV ED PRIM
  • [4] [Anonymous], CERV CANC LIB HPV VA
  • [5] Achieving high coverage in Rwanda's national human papillomavirus vaccination programme
    Binagwaho, Agnes
    Wagner, Claire M.
    Gatera, Maurice
    Karema, Corine
    Nutt, Cameron T.
    Ngabo, Fidele
    [J]. BULLETIN OF THE WORLD HEALTH ORGANIZATION, 2012, 90 (08) : 623 - 628
  • [6] The Multiple Purposes of Policy Piloting and Their Consequences: Three Examples from National Health and Social Care Policy in England
    Ettelt, Stefanie
    Mays, Nicholas
    Allen, Pauline
    [J]. JOURNAL OF SOCIAL POLICY, 2015, 44 (02) : 319 - 337
  • [7] Gallagher K, 2015, 30 INT PAP C HPV 201
  • [8] Gavi Alliance, 2014, SUPPL GUID HUM PAP H
  • [9] LaMontagne DS, 2011, B WORLD HEALTH ORGAN, V89, P821, DOI [10.2471/BLT.11.08986, 10.2471/BLT.11.089862]
  • [10] Qiagen, 2015, MERCK QIAG IN QIAG C